Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study. News GSK backs £50m Oxford University cancer vaccine programme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback